TMCI
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 4.31 · operating margin -25% — readings disagree
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 55 944 titres (~246 654,31 $ US)
- Insiders
- Treace John T.
- Total bought
-
$246,654
Avg buy (VWAP, 90d window) $4.41 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-08-24
- Last synced
-
2026-08-30 10:16:45
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-24 | Treace John T. | Buy | 11,000 | $4.34 | $47,731 | Form 4 |
| 2026-08-21 | Treace John T. | Buy | 5,000 | $4.35 | $21,748 | Form 4 |
| 2026-08-20 | Treace John T. | Buy | 39,944 | $4.44 | $177,176 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-08-26
TMCI presents a deeply unfavorable risk/reward profile: severe financial distress with persistent losses, negative profitability metrics (ROE, ROA, ROIC), and no visible path to positive cash flow undermine any bullish…
The first sentence of the analysis written for TMCI on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 79.8% | 80.4% | 81.2% | 80.6% | 82.1% | |
| Ebit Margin | -25.2% | -24.1% | -23.7% | -27.1% | -17.5% | |
| Ebitda Margin | -20.3% | -20.1% | -20.8% | -25.6% | -16.7% | |
| Operating Profit Margin | -25.5% | -26.6% | -27.5% | -24.6% | -17.5% | |
| Pretax Profit Margin | -27.7% | -26.6% | -26.5% | -30.2% | -21.8% | |
| Continuous Operations Profit Margin | -27.7% | -26.6% | -26.5% | -30.2% | -21.8% | |
| Net Profit Margin | -27.7% | -26.6% | -26.5% | -30.2% | -21.8% | |
| Bottom Line Profit Margin | -27.7% | -26.6% | -26.5% | -30.2% | -22.0% | |
| Current Ratio | 4.311 | 4.621 | 4.405 | 4.411 | 7.577 | |
| Quick Ratio | 3.134 | 3.497 | 3.755 | 3.772 | 6.997 | |
| Solvency Ratio | -0.470 | -0.454 | -0.388 | -0.413 | -0.416 | |
| Cash Ratio | 0.350 | 0.325 | 0.288 | 0.644 | 5.812 | |
| Price To Earnings Ratio | -2.634 | -8.267 | -15.741 | -29.857 | -49.053 | |
| Price To Earnings Growth Ratio | -0.790 | -0.744 | -3.030 | -0.291 | -0.140 | |
| Forward Price To Earnings Growth Ratio | -0.790 | -0.744 | -3.030 | -0.291 | -0.140 | |
| Price To Earnings Diluted Ratio | -2.634 | -8.267 | -15.741 | -29.857 | -49.053 | |
| Price To Earnings Diluted Growth Ratio | -0.790 | -0.744 | -3.030 | -0.291 | -0.140 | |
| Price To Book Ratio | 1.775 | 4.093 | 5.625 | 20.995 | 10.851 | |
| Price To Sales Ratio | 0.729 | 2.207 | 4.146 | 8.960 | 10.696 | |
| Price To Free Cash Flow Ratio | -5.257 | -9.477 | -16.855 | -27.939 | -50.756 | |
| Price To Operating Cash Flow Ratio | -9.706 | -12.433 | -22.440 | -41.465 | -58.741 | |
| Debt To Assets Ratio | 0.073 | 0.321 | 0.279 | 0.431 | 0.209 | |
| Debt To Equity Ratio | 0.160 | 0.617 | 0.510 | 1.133 | 0.316 | |
| Debt To Capital Ratio | 0.138 | 0.382 | 0.338 | 0.531 | 0.240 | |
| Long Term Debt To Capital Ratio | 0.138 | 0.321 | 0.278 | 0.465 | 0.240 | |
| Financial Leverage Ratio | 2.182 | 1.923 | 1.826 | 2.627 | 1.513 | |
| Working Capital Turnover Ratio | 1.867 | 1.496 | 1.459 | 1.273 | 1.266 | |
| Operating Cash Flow Ratio | -0.521 | -1.064 | -0.768 | -1.013 | -0.944 | |
| Operating Cash Flow Sales Ratio | -0.075 | -0.178 | -0.185 | -0.216 | -0.182 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.846 | 1.312 | 1.331 | 1.484 | 1.157 | |
| Debt Service Coverage Ratio | -8.117 | -8.004 | -7.549 | -8.250 | -3.893 | |
| Interest Coverage Ratio | -10.179 | -10.595 | -9.953 | -7.923 | -4.067 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.142 | -0.534 | -0.492 | -0.447 | -0.585 | |
| Capital Expenditure Coverage Ratio | -1.181 | -3.206 | -3.018 | -2.066 | -6.356 | |
| Dividend Paid And Capex Coverage Ratio | -1.181 | -3.206 | -3.018 | -2.066 | -6.356 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.665 | -12.371 | -21.359 | -36.378 | -59.054 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 79.8% | ▼-0.6% | ▼-1.0% |
| Ebit Margin | -25.2% | ▼-1.1% | ▼-1.7% |
| Ebitda Margin | -20.3% | ▼-0.2% | ▲0.4% |
| Operating Profit Margin | -25.5% | ▲1.1% | ▼-1.1% |
| Pretax Profit Margin | -27.7% | ▼-1.1% | ▼-1.2% |
| Continuous Operations Profit Margin | -27.7% | ▼-1.1% | ▼-1.2% |
| Net Profit Margin | -27.7% | ▼-1.1% | ▼-1.2% |
| Bottom Line Profit Margin | -27.7% | ▼-1.1% | ▼-1.1% |
| Current Ratio | 4.311 | ▼-0.311 | ▼-0.754 |
| Quick Ratio | 3.134 | ▼-0.363 | ▼-1.097 |
| Solvency Ratio | -0.470 | ▼-0.016 | ▼-0.042 |
| Cash Ratio | 0.349 | ▲0.025 | ▼-1.134 |
| Price To Earnings Ratio | -2.634 | ▲5.632 | ▲18.476 |
| Price To Earnings Growth Ratio | -0.790 | ▼-0.046 | ▲0.209 |
| Forward Price To Earnings Growth Ratio | -0.790 | ▼-0.046 | ▲0.209 |
| Price To Earnings Diluted Ratio | -2.634 | ▲5.632 | ▲18.476 |
| Price To Earnings Diluted Growth Ratio | -0.790 | ▼-0.046 | ▲0.209 |
| Price To Book Ratio | 1.775 | ▼-2.318 | ▼-6.893 |
| Price To Sales Ratio | 0.729 | ▼-1.478 | ▼-4.619 |
| Price To Free Cash Flow Ratio | -5.257 | ▲4.220 | ▲16.800 |
| Price To Operating Cash Flow Ratio | -9.706 | ▲2.727 | ▲19.251 |
| Debt To Assets Ratio | 0.073 | ▼-0.247 | ▼-0.189 |
| Debt To Equity Ratio | 0.160 | ▼-0.457 | ▼-0.387 |
| Debt To Capital Ratio | 0.138 | ▼-0.244 | ▼-0.188 |
| Long Term Debt To Capital Ratio | 0.138 | ▼-0.183 | ▼-0.150 |
| Financial Leverage Ratio | 2.182 | ▲0.259 | ▲0.168 |
| Working Capital Turnover Ratio | 1.867 | ▲0.370 | ▲0.394 |
| Operating Cash Flow Ratio | -0.521 | ▲0.543 | ▲0.341 |
| Operating Cash Flow Sales Ratio | -0.075 | ▲0.102 | ▲0.092 |
| Free Cash Flow Operating Cash Flow Ratio | 1.846 | ▲0.534 | ▲0.420 |
| Debt Service Coverage Ratio | -8.117 | ▼-0.113 | ▼-0.954 |
| Interest Coverage Ratio | -10.179 | ▲0.416 | ▼-1.636 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -1.142 | ▼-0.609 | ▼-0.502 |
| Capital Expenditure Coverage Ratio | -1.181 | ▲2.025 | ▲1.984 |
| Dividend Paid And Capex Coverage Ratio | -1.181 | ▲2.025 | ▲1.984 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.666 | ▲8.705 | ▲22.900 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $155.0M | $462.1M | $775.9M | $1.27B | $1.01B | |
| Enterprise value | $158.3M | $520.4M | $833.2M | $1.32B | $933.5M | |
| EV / Sales | 0.74x | 2.49x | 4.45x | 9.31x | 9.89x | |
| EV / Op. cash flow | -9.91x | -14.00x | -24.10x | -43.07x | -54.29x | |
| EV / Free cash flow | -5.37x | -10.67x | -18.10x | -29.02x | -46.91x | |
| EV / EBITDA | -3.67x | -12.37x | -21.36x | -36.38x | -59.05x | |
| Net debt / EBITDA | -0.08x | -1.39x | -1.47x | -1.35x | 4.84x | |
| Current ratio | 4.31x | 4.62x | 4.41x | 4.41x | 7.58x | |
| Income quality | 0.27x | 0.67x | 0.70x | 0.72x | 0.84x | |
| Graham net-net | -$0 | $0 | $1 | $0 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 109.9% | 110.4% | 111.6% | 111.4% | 124.6% | |
| Working capital | $101.4M | $126.5M | $153.3M | $103.2M | $119.8M | |
| Invested capital | $158.7M | $181.8M | $206.7M | $128.6M | $122.6M | |
| Return on assets | -31.0% | -25.7% | -19.7% | -26.9% | -14.6% | |
| Operating ROA | -26.6% | -23.7% | -25.0% | -23.2% | -18.1% | |
| Return on tangible assets | -34.6% | -28.4% | -21.5% | -26.9% | -14.6% | |
| Return on equity | -67.6% | -49.4% | -35.9% | -70.7% | -22.1% | |
| Return on invested capital | -33.9% | -30.5% | -24.7% | -27.0% | -13.5% | |
| Return on capital employed | -33.9% | -30.6% | -24.9% | -27.1% | -13.5% | |
| Earnings yield | -38.1% | -12.1% | -6.4% | -3.4% | -2.0% | |
| Free cash flow yield | -19.0% | -10.6% | -5.9% | -3.6% | -2.0% | |
| Capex / Op. cash flow | -84.6% | -31.2% | -33.1% | -48.4% | -15.7% | |
| Capex / Depreciation | 128.7% | 137.7% | 214.1% | 695.6% | 394.9% | |
| Capex / Sales | 6.4% | 5.5% | 6.1% | 10.5% | 2.9% | |
| SG&A / Sales | 95.7% | 97.1% | 100.4% | 97.0% | 88.8% | |
| R&D / Sales | 9.5% | 9.8% | 8.3% | 9.6% | 10.8% | |
| Stock comp / Sales | 15.9% | 14.6% | 9.3% | 5.7% | 3.6% | |
| Intangibles / Total assets | 10.5% | 9.6% | 8.7% | 0.0% | 0.0% | |
| Days sales outstanding | 72d | 71d | 74d | 75d | 72d | |
| Days payables outstanding | 57d | 93d | 123d | 115d | 88d | |
| Operating cycle | 379d | 420d | 378d | 331d | 300d | |
| Cash conversion cycle | 321d | 326d | 255d | 217d | 212d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-66.5%EV / Sales ▼-70.1%EV / EBITDA ▲+70.4%EV / Op. cash flow ▲+4.091Earnings yield ▼-0.260
Profitability
Return on equity ▼-0.182Return on assets ▼-0.053Return on invested capital ▼-0.034Return on capital employed ▼-0.033Operating ROA ▼-0.028Income quality ▼-0.396Tax burden 0.000
Efficiency
Days sales outstanding ▲+1.205Days payables outstanding ▼-36.284Operating cycle ▼-41.183Cash conversion cycle ▼-4.899Capex / Sales ▲+0.008R&D / Sales ▼-0.003
Balance-sheet strength
Current ratio ▼-0.311Net debt / EBITDA ▲+1.310Working capital ▼-25058000.000Invested capital ▼-23037000.000Intangibles / Total assets ▲+0.008
Change over 5 years
Valuation
Market cap ▼-84.7%EV / Sales ▼-92.5%EV / EBITDA ▲+93.8%EV / Op. cash flow ▲+44.382Earnings yield ▼-0.360
Profitability
Return on equity ▼-0.455Return on assets ▼-0.164Return on invested capital ▼-0.204Return on capital employed ▼-0.204Operating ROA ▼-0.085Income quality ▼-0.566Tax burden 0.000
Efficiency
Days sales outstanding ▲+0.564Days payables outstanding ▼-30.487Operating cycle ▲+78.595Cash conversion cycle ▲+109.082Capex / Sales ▲+0.035R&D / Sales ▼-0.013
Balance-sheet strength
Current ratio ▼-3.266Net debt / EBITDA ▼-4.913Working capital ▼-18343000.000Invested capital ▲+36114000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-07 Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
- 2026-08-07 Treace Medical Concepts Q2 Earnings Call Highlights Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products weighed on reported sales.
- 2026-08-07 Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.
- 2026-08-07 Treace Medical Concepts Reports Second Quarter 2026 Financial Results PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026.
- 2026-07-24 Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
- 2026-07-24 Treace to Report Second Quarter 2026 Financial Results on August 7, 2026 PONTE VEDRA, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the second quarter 2026 before the start of trading on Friday, August 7, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.
- 2026-07-13 Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI) SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) against certain of its officers and directors for alleged breaches of fiduciary duty.
- 2026-06-18 Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace''s comprehensive suite of technologies for its growing customer base New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace''s comprehensive suite of technologies for its growing customer base
- 2026-06-11 Treace to Present at the Sidoti Small Cap Conference PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will present at the Sidoti Small Cap Conference, Thursday, June 18, 2026, beginning at approximately 1:45 pm ET.